Javascript must be enabled to continue!
In memoriam of Evgeny Iosifovich Schwartz
View through CrossRef
E.I. Schwartz stood at the foundation of Russian molecular genetics: he was the first to apply the novel method of polymerase chain reaction (PCR) in this country. E.I. Schwartz graduated from the LPMI at 1967. His area of research belonged at first to the realm of the metabolic manifestations of hereditary diseases. Since 1985, he began working at the Laboratory of Molecular Genetics, Leningrad Institute of Nuclear Physics (LINP). Shortly thereafter, E.I.Schwartz began to reproduce and implement the PCR, recently proposed by K. Mullis. Coincidentally, the seemingly purely fundamental studies of thermostable polymerase, which turned out to be the key PCR enzyme, had been independently conducted in LINP and contributed to the success of E.I. Schwartz undertaking. He also initiated the development of the first Russian thermocyclers. He implemented PCR in fruitful long-term research projects on the molecular epidemiology of monogenic diseases: phenylketonuria, familial hypercholesterolemia, hereditary disorders of hemostasis, etc. E.I. Schwartz optimized the methods of isolating nucleic acids from dried blood spots and other sources, suboptimal for a laboratory specialist, but ideal for screening and forensic practice. Another field of hisresearch was to elucidate the role of polymorphic alleles in multifactorial diseases. E.I. Schwartz enthusiastically propagated the new molecular approaches among clinicians and laboratory geneticists: he established close and fruitful collaborations between specialists of the vastly divergent backgrounds. In 1989 E.I. Schwartz founded the Department of Medical Genetics of LPMI, which was one of the first such departments in U.S.S.R. In 2001, he founded the Department of Molecular Genetic Technologies in I.P. Pavlov`s St.Petersburg State Medical University. In 2003, E.I. Schwartz has passed away, leaving behind him the good memory of numerous students and successors of his work
Title: In memoriam of Evgeny Iosifovich Schwartz
Description:
E.
I.
Schwartz stood at the foundation of Russian molecular genetics: he was the first to apply the novel method of polymerase chain reaction (PCR) in this country.
E.
I.
Schwartz graduated from the LPMI at 1967.
His area of research belonged at first to the realm of the metabolic manifestations of hereditary diseases.
Since 1985, he began working at the Laboratory of Molecular Genetics, Leningrad Institute of Nuclear Physics (LINP).
Shortly thereafter, E.
I.
Schwartz began to reproduce and implement the PCR, recently proposed by K.
Mullis.
Coincidentally, the seemingly purely fundamental studies of thermostable polymerase, which turned out to be the key PCR enzyme, had been independently conducted in LINP and contributed to the success of E.
I.
Schwartz undertaking.
He also initiated the development of the first Russian thermocyclers.
He implemented PCR in fruitful long-term research projects on the molecular epidemiology of monogenic diseases: phenylketonuria, familial hypercholesterolemia, hereditary disorders of hemostasis, etc.
E.
I.
Schwartz optimized the methods of isolating nucleic acids from dried blood spots and other sources, suboptimal for a laboratory specialist, but ideal for screening and forensic practice.
Another field of hisresearch was to elucidate the role of polymorphic alleles in multifactorial diseases.
E.
I.
Schwartz enthusiastically propagated the new molecular approaches among clinicians and laboratory geneticists: he established close and fruitful collaborations between specialists of the vastly divergent backgrounds.
In 1989 E.
I.
Schwartz founded the Department of Medical Genetics of LPMI, which was one of the first such departments in U.
S.
S.
R.
In 2001, he founded the Department of Molecular Genetic Technologies in I.
P.
Pavlov`s St.
Petersburg State Medical University.
In 2003, E.
I.
Schwartz has passed away, leaving behind him the good memory of numerous students and successors of his work.
Related Results
Maurice Schwartz
Maurice Schwartz
The actor-manager Maurice Schwartz (b. 1888–d. 1960) was a towering figure of the modern Yiddish stage. Born Moshe Schwartz in Sudilkov, a small town in the Ukraine, Schwartz came ...
Le théâtre de Evgueni Schwartz et le discours politique de l’opposition russe
Le théâtre de Evgueni Schwartz et le discours politique de l’opposition russe
Evgeny Schwartz’s plays and the political discourse of the Russian opposition
Fairy tales by the Soviet playwright Evgeny Schwartz (1896-1958) are among the most quoted liter...
McCulloch v. Madison: John Marshall's Effort to Bury Madisonian Federalism
McCulloch v. Madison: John Marshall's Effort to Bury Madisonian Federalism
In his engaging and provocative new book, The Spirit of the Constitution: John Marshall and the 200-Year Odyssey of McCulloch v. Maryland, David S. Schwartz challenges McCulloch’s ...
MPD physics performance studies in Bi+Bi collisions at √sNN = 9.2 GeV
MPD physics performance studies in Bi+Bi collisions at √sNN = 9.2 GeV
TheMulti-Purpose Detector (MPD) is one of the three experiments of the Nuclotron Ion Collider-fAcility (NICA) complex, which is currently under construction at the Joint Institute ...
Szwedzkie matki powieści na ziemiach polskich. Fenomen Marie Sophie Schwartz w perspektywie transkulturowej
Szwedzkie matki powieści na ziemiach polskich. Fenomen Marie Sophie Schwartz w perspektywie transkulturowej
Artykuł przedstawia w zarysie falę popularności powieści szwedzkich pisarek w II połowie XIX wieku na terenach polskich, co znalazło wyraz w licznych polskich przekładach ich dzieł...
In Memoriam Jean Baudrillard
In Memoriam Jean Baudrillard
Author(s): Bobi Badarevski | Боби Бадаревски
Title (English): In Memoriam Jean Baudrillard
Title (Macedonian): In Memoriam Жан Бодријар
Translated by (Macedonian ...
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
OBJECTIVE
In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of...

